KR102383824B1 - 암 치료법을 위한 메트로놈 경구 젬시타빈 - Google Patents

암 치료법을 위한 메트로놈 경구 젬시타빈 Download PDF

Info

Publication number
KR102383824B1
KR102383824B1 KR1020187038225A KR20187038225A KR102383824B1 KR 102383824 B1 KR102383824 B1 KR 102383824B1 KR 1020187038225 A KR1020187038225 A KR 1020187038225A KR 20187038225 A KR20187038225 A KR 20187038225A KR 102383824 B1 KR102383824 B1 KR 102383824B1
Authority
KR
South Korea
Prior art keywords
gem
delete delete
formulation
oral
mice
Prior art date
Application number
KR1020187038225A
Other languages
English (en)
Korean (ko)
Other versions
KR20190015420A (ko
Inventor
웨이-후아 하오
수-핑 슈에
창-샨 수
Original Assignee
이노파막스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이노파막스, 인크. filed Critical 이노파막스, 인크.
Publication of KR20190015420A publication Critical patent/KR20190015420A/ko
Application granted granted Critical
Publication of KR102383824B1 publication Critical patent/KR102383824B1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020187038225A 2016-06-02 2017-06-02 암 치료법을 위한 메트로놈 경구 젬시타빈 KR102383824B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662344660P 2016-06-02 2016-06-02
US62/344,660 2016-06-02
PCT/CN2017/086942 WO2017206940A1 (en) 2016-06-02 2017-06-02 Metronomic oral gemcitabine for cancer therapy

Publications (2)

Publication Number Publication Date
KR20190015420A KR20190015420A (ko) 2019-02-13
KR102383824B1 true KR102383824B1 (ko) 2022-04-06

Family

ID=60479058

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187038225A KR102383824B1 (ko) 2016-06-02 2017-06-02 암 치료법을 위한 메트로놈 경구 젬시타빈

Country Status (10)

Country Link
US (1) US10835548B2 (zh)
EP (1) EP3463298B1 (zh)
JP (2) JP2019517490A (zh)
KR (1) KR102383824B1 (zh)
CN (2) CN114224865A (zh)
AU (1) AU2017273495B2 (zh)
CA (1) CA3026144A1 (zh)
ES (1) ES2898024T3 (zh)
TW (1) TWI814703B (zh)
WO (1) WO2017206940A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020247912A1 (en) * 2019-06-06 2020-12-10 Board Of Regents, The University Of Texas System Lipid nanoparticles containing pharmaceutical and/or nutraceutical agents and methods thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE038768T2 (hu) 2005-02-18 2018-11-28 Abraxis Bioscience Llc Terápiás szerek kombinációi, valamint beadásukra szolgáló módszerek, és kombinációs terápia
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
RS59607B1 (sr) 2008-09-23 2020-01-31 Nektar Therapeutics Metod metronomskog doziranja kamptotecinskih prolekova (npr. peg-irinotekan)
WO2010039039A1 (en) * 2008-10-03 2010-04-08 Clavis Pharma Asa Oral formulations of gemcitabine derivatives
US20100273730A1 (en) * 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
CN101926779A (zh) * 2010-08-19 2010-12-29 苏州特瑞药业有限公司 一种吉西他滨固体脂质纳米粒及其制备方法与用途
WO2013058294A1 (ja) * 2011-10-18 2013-04-25 味の素株式会社 膵臓癌及び／又は胆道癌治療薬
US20150283237A1 (en) * 2014-04-02 2015-10-08 Mitchell S. Felder Ctla-4 blockade with metronomic chemotherapy for the treatment of cancer

Also Published As

Publication number Publication date
CA3026144A1 (en) 2017-12-07
CN114224865A (zh) 2022-03-25
AU2017273495A1 (en) 2018-12-20
JP2019517490A (ja) 2019-06-24
EP3463298A4 (en) 2020-01-01
US20170348341A1 (en) 2017-12-07
CN109310631A (zh) 2019-02-05
KR20190015420A (ko) 2019-02-13
TW201808309A (zh) 2018-03-16
US10835548B2 (en) 2020-11-17
ES2898024T3 (es) 2022-03-03
TWI814703B (zh) 2023-09-11
WO2017206940A1 (en) 2017-12-07
AU2017273495B2 (en) 2023-01-12
EP3463298A1 (en) 2019-04-10
JP2022088622A (ja) 2022-06-14
EP3463298B1 (en) 2021-09-01

Similar Documents

Publication Publication Date Title
Zhai et al. Drug delivery systems for elemene, its main active ingredient β-elemene, and its derivatives in cancer therapy
RU2532362C2 (ru) Самомикроэмульгирующаяся оральная фармацевтическая композиция, содержащая гидрофильное лекарственное средство, и способ ее приготовления
Chang et al. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy
CA3149460C (en) Drug composition containing abiraterone acetate, and preparation method therefor and application thereof
US20070104780A1 (en) Formulation comprising a drug of low water solubility and method of use thereof
JP2002509877A (ja) 抗癌組成物
CN108697683B (zh) 口服紫杉烷组合物和方法
ES2688817T3 (es) Formulación en cápsulas solubilizadas de [(1S)-1-{[(2S,4R)-4-(7-cloro-4metoxiisoquinolin-1-iloxi)-2-({(1R,2S)-1-[(ciclopropilsulfonil)carbamoil]-2-etenilciclopropil}carbamoil)pirrolidin-1-il]carbonil}-2,2-dimetilpropil]carbamato de 1,1-dimetiletilo
Doi et al. Combination therapy of metronomic S‐1 dosing with oxaliplatin‐containing polyethylene glycol‐coated liposome improves antitumor activity in a murine colorectal tumor model
KR20210005714A (ko) 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조합 조성물 및 이의 사용 방법
ES2551125T3 (es) Composición antifúngica
KR102383824B1 (ko) 암 치료법을 위한 메트로놈 경구 젬시타빈
JP6484393B2 (ja) デュタステリドを含有する医薬組成物及びそれを含むカプセル製剤
EA016619B1 (ru) Новые композиции на основе таксоидов
Riebesehl Drug delivery with organic solvents or colloidal dispersed systems
AU2004262496B2 (en) Semi-solid formulations for the oral administration of taxoids
US20160317540A1 (en) Therapeutic Treatment
US8541465B2 (en) Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
JP2022088622A5 (zh)
NZ616410B2 (en) Combination treatment of cancer

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant